Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GR2301 in Healthy Adult Participants
NCT07647224Phase 1Not yet recruiting
- Sponsor
- Zhixiang Jintai
- Start
- Jun 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GR2301 (3 arms), sponsored by Zhixiang Jintai. Primary endpoint: Adverse events at 52 weeks. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
GR2301
Beyond the preview
Go deeper on NCT07647224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07647224.